US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Eli Lilly and Company

LLYNYSE

342.10

USD
-5.91
(-1.70%)
Market Closed
51.44P/E
42Forward P/E
2.59P/E to S&P500
325.056BMarket CAP
1.09%Div Yield
Upcoming Earnings
2 Feb
Shares Short
1/13/23
4.93M
Short % of Float
0.62%
Short % of Shares Outs.
0.52%
% Held by Insiders
0.15%
% Held by Institutions
84.83%
Beta
0.38
PEG Ratio
2.54
52w. high/low
384.44/231.87
Avg. Daily Volume
2.83M
Return %
Stock
S&P 500
1 year
42.46
(6.69)
3 years
144.25
24.00
5 years
291.02
42.28
Scale: |
High
Low
57.52
28.62
40.78
27.21
38.08
32.02
41.92
33.46
53.99
38.30
58.40
47.53
75.10
50.52
92.85
68.31
85.40
64.18
89.09
73.54
119.84
73.69
137.00
101.36
173.90
117.06
283.90
161.78
375.25
231.87
384.44
302.14
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
14.44
17.10
18.62
19.88
20.87
21.80
19.72
20.70
17.66
18.06
19.28
21.74
23.89
23.31
25.65
31.22
31.97
Earnings per share
2.45
2.71
(1.89)
3.94
4.58
3.90
3.57
4.19
2.15
2.18
2.49
(0.19)
3.14
8.69
6.47
6.15
6.59
FCF per share
2.67
3.74
5.80
3.17
5.13
4.97
3.72
4.16
2.52
1.04
3.41
3.28
2.44
3.64
4.67
5.94
5.84
Dividends per share
1.60
1.70
1.88
1.96
1.96
1.96
1.91
1.90
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.40
3.74
CAPEX per share
0.99
0.99
0.87
0.78
1.07
1.52
0.91
0.98
1.41
1.47
0.99
2.06
2.94
1.41
2.12
2.07
2.54
Book Value per sh.
10.10
12.54
6.15
8.67
11.23
12.16
12.88
15.79
13.84
13.18
12.72
11.02
9.56
2.72
5.90
9.90
10.09
Comm.Shares outs.
1,087
1,090
1,094
1,098
1,106
1,114
1,146
1,117
1,111
1,105
1,101
1,052
1,028
958
957
907
915
Avg. annual P/E ratio
- -
20.4
(24.1)
8.7
7.7
9.4
12.2
12.6
28.7
36.3
30.7
(423.4)
29.7
13.4
22.7
36.4
51.4
P/E to S&P500
- -
1.2
(1.1)
0.1
0.4
0.6
0.8
0.7
1.6
1.8
1.4
(17.9)
1.2
0.6
0.6
1.2
2.6
Avg. annual div. yield
- -
3.1%
4.1%
5.7%
5.6%
5.3%
4.4%
3.6%
3.1%
2.4%
2.6%
2.5%
2.4%
2.2%
1.9%
1.5%
1.2%
Revenue (m)
15,691
18,634
20,378
21,836
23,076
24,287
22,603
23,113
19,616
19,959
21,222
22,871
24,556
22,320
24,540
28,318
29,240
Operating margin
26.3%
25.8%
27.1%
29.2%
29.3%
22.8%
20.9%
23.2%
13.6%
13.5%
16.3%
9.4%
25.2%
22.3%
24.7%
22.4%
27.1%
Depreciation (m)
802
1,048
1,123
1,298
1,328
1,374
1,462
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,593
Net profit (m)
2,663
2,953
(2,072)
4,329
5,070
4,348
4,089
4,685
2,391
2,408
2,738
(204)
3,232
8,318
6,194
5,582
6,033
Income tax rate
22.1%
23.8%
(58.5)%
19.2%
22.3%
18.7%
24.4%
20.5%
20.3%
13.7%
18.9%
109.3%
14.9%
11.9%
14.3%
9.3%
8.4%
Net profit margin
17.0%
15.8%
(10.2)%
19.8%
22.0%
17.9%
18.1%
20.3%
12.2%
12.1%
12.9%
(0.9)%
13.2%
37.3%
25.2%
19.7%
20.4%
Working capital (m)
4,609
6,989
(656)
5,918
7,739
5,317
4,649
4,188
972
4,344
4,115
4,666
8,662
1,934
4,981
3,400
1,987
Long-term debt (m)
3,494
4,594
4,616
6,635
6,771
5,465
5,519
4,200
5,368
7,972
8,368
9,941
11,640
13,818
16,587
15,346
14,144
Equity (m)
10,981
13,664
6,735
9,524
12,420
13,542
14,765
17,631
15,373
14,571
14,008
11,592
9,829
2,607
5,642
8,979
10,070
ROIC
15.8%
13.7%
(12.9)%
21.7%
21.8%
18.2%
16.2%
18.3%
9.7%
9.3%
10.4%
(0.7)%
11.2%
30.0%
19.1%
17.5%
19.9%
Return on capital
15.6%
14.5%
(4.5)%
20.5%
21.6%
16.4%
16.2%
17.2%
8.5%
8.3%
9.2%
5.4%
9.5%
23.8%
16.3%
13.4%
14.5%
Return on equity
24.2%
21.6%
(30.8)%
45.5%
40.8%
32.1%
27.7%
26.6%
15.5%
16.5%
19.5%
(1.8)%
32.9%
319.1%
109.8%
62.2%
59.9%
Plowback ratio
34.8%
37.2%
199.3%
50.3%
57.3%
49.9%
46.5%
54.7%
12.1%
11.7%
21.2%
1,174.0%
28.5%
71.0%
56.6%
44.7%
43.2%
Div.&Repurch./FCF
62.1%
44.9%
- -
61.8%
38.2%
39.3%
68.3%
82.3%
103.6%
250.9%
73.4%
- -
191.6%
195.5%
71.3%
80.5%
106.3%
Capital Structure
1 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 37,296
Total assets
$ 47,462
Long-term debt
$ 14,144
Cash and equiv.
$ 2,617
Goodwill
$ 3,892
Retained earnings
$ 10,007
Common stock
901
Enterprise Value
$ 336,582
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
2,439
3,681
3,909
Receivables
5,542
6,929
8,127
Inventory
3,191
3,980
3,886
Other
2,539
4,191
4,012
Current assets
13,710
17,462
18,452
Acc. Payable
1,405
1,607
1,671
Debt due
1,499
9
1,538
Other
8,871
10,866
11,844
Current liabilities
11,775
12,482
15,053
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
15.40%
5.90%
2.95%
Cash flow
20.51%
15.11%
21.15%
Earnings
(9.88)%
(390.40)%
(187.67)%
Dividends
14.87%
9.02%
4.04%
Book value
59.16%
21.72%
7.46%
Insider Trading
Type
Shares
Date
Tai Jackson P
Award
6
01/17/23
Sulzberger Gabrielle
Award
14
01/17/23
Luciano Juan R
Award
40
01/17/23
Johnson Kimberly H
Award
27
01/17/23
Fyrwald J Erik
Award
28
01/17/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
5,860
5,499
5,741
7,440
24,540
2021
6,806
6,740
6,773
8,000
28,318
2022
7,810
6,488
6,942
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.52
1.48
1.26
2.21
6.47
2021
1.49
1.53
1.22
1.90
6.15
2022
2.11
1.06
1.61
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.70
0.70
0.70
0.70
2.81
2021
0.85
0.85
0.85
0.85
3.40
2022
0.98
0.98
0.98
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. David Ricks
Full-time employees:
35,000
City:
Indianapolis
Address:
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
IPO:
Jul 9, 1970
Website:
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Recent News
· 4 Dec, 2022 · The Wall Street Journal
· 30 Nov, 2022 · The Wall Street Journal
· 6 Aug, 2022 · The Wall Street Journal
· 5 Aug, 2022 · The Wall Street Journal
· 29 Jun, 2022 · The Wall Street Journal
· 21 Jun, 2022 · The Wall Street Journal
· 24 May, 2022 · The Wall Street Journal
· 24 Mar, 2022 · The Wall Street Journal
· 26 Oct, 2021 · The Wall Street Journal
· 30 Jul, 2021 · The Wall Street Journal
· 24 Jun, 2021 · The Wall Street Journal
· 16 Apr, 2021 · The Wall Street Journal